Anaphore Announces $25 Million Series A Financing

This post was commissioned on January 7, 2009, and it was categorized as Venture Capital, funding.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Anaphore announced it has raised $25 million in Series A financing led by 5AM Ventures, Versant Ventures, and Apposite Capital. Not a bad haul for a Series A in this environment. Proceeds from the financing will be used to accelerate development of Atrimers™ – a new class of protein therapeutics Anaphore is developing to address significant unmet medical needs in immune-mediated diseases and oncology.

Only 7 days into the new year, we have the first company to make up a name for its class of drug candidates. See the description below:

“Atrimers are novel drug candidates engineered from a fully-human serum protein that is naturally secreted as a trimeric structure. Anaphore’s proprietary protein engineering platform – TrimerX™ – provides multiple approaches to generate Atrimers, therapeutics with biological, manufacturing and commercial advantages over traditional drugs such as antibodies, smaller protein scaffolds, and small molecules. Atrimers and the TrimerX platform are protected by significant intellectual property including over thirteen patent families.”

Anaphore, Inc. Raises $25 Million
(Via BioSpace.com Featured News and Stories.)

Theoretically Related Posts

April 16, 2009 -- Lycera Closes $36 Million Series A (0)
February 24, 2009 -- Heptares Secures $30M in Series A Funding (0)
January 9, 2009 -- Kolltan Raises over $35 Million in Series A Haul (0)
November 24, 2008 -- Exelixis and Bristol-Myers Squibb to Co-Develop a Selective Cdc7 Inhibitor (2)
November 18, 2008 -- Numerate Completes $4 Million Series A (0)
November 17, 2008 -- Pacira Pharmaceuticals Raises $85 Million in Series A (2)
November 10, 2008 -- ArQule and Daiichi Sankyo Ink c-Met and Discovery Deals (0)
November 10, 2008 -- Precision Therapeutics Secures $43 Million in VC Funding (0)
November 10, 2008 -- BTG Inks $320 Million Preclinical Deal With Onyx (0)
October 30, 2008 -- Alnara Pharmaceuticals, Inc. Secures $20 Million in Series A Round (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: